Oncotarget

Research Papers:

Prognostic value of microRNAs in cervical carcinoma: a systematic review and meta-analysis

Shengkang Dai, Yan Lu, Ying Long, Yuehua Lai, Ping Du, Nan Ding and Desheng Yao _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2016; 7:35369-35378. https://doi.org/10.18632/oncotarget.9294

Metrics: PDF 1005 views  |   HTML 897 views  |   ?  


Abstract

Shengkang Dai1, Yan Lu1, Ying Long1, Yuehua Lai1, Ping Du1, Nan Ding1, Desheng Yao1

1Department of Gynecologic Oncology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China

Correspondence to:

Desheng Yao, e-mail: yaodeson@163.com

Keywords: microRNA, prognosis, cervical carcinoma, meta-analysis

Received: December 08, 2015    Accepted: April 11, 2016    Published: May 11, 2016

ABSTRACT

This systematic review is written to investigate the outcome of cervical cancer. A comprehensive search of PubMed and EMBASE was performed to identify eligible studies. Nineteen studies from thirteen articles with a total of 1,310 participants were included in this meta-analysis. Overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) as a prognosis for cervical cancer were extracted and calculated, if available. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using STATA (version 12.0), resulting in the pooled HRs 0.70 (95% CI: 0.51–0.97) for OS, 1.02 (95% CI: 0.53–1.98) for DFS, and 0.56 (95% CI: 0.40–0.77) for RFS. The results indicated that cervical cancer patients with decreased microRNA expression were associated with shorter OS and RFS. It suggested that microRNAs might be promising markers for predicting the survival rate of cervical cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9294